Understanding the Potential of Organoids: Market Insights By 2023 to 2033

BySanket Badgujar
Organoids Market

A recent Future Market Insights analysis projects that the worldwide organoids market will expand between 2023 and 2033 at a CAGR of 13%. The market is anticipated to be worth US$ 205.3 million by the end of the forecast period. In 2023, the market is expected to be worth US$ 60.4 million.

Organoids are microscopic, self-organizing, 3D structures that are developed in vitro from stem cells. Multiple innovative human cancer models have been created as a result of this multifunctional invention. It is anticipated that organoids will continue to be employed more and more in a range of applications, including pathogenesis, disease models, regenerative medicine, and drug screening.

To Remain Ahead of Your Competitors, Request For A Sample! https://www.futuremarketinsights.com/reports/sample/rep-gb-8106

Developments in research in the field are driving the global organoids market. Additionally, the growing trend toward personalized medicine are expected to increase the use of organoids in future decades.

Key Takeaways:

  • According to FMI’s analysis, the organoids market developed at a 15.6% CAGR over the previous decade.
  • In 2022, the United States held a 46.1% market share.
  • In 2022, Japan accounted for a 4.7% percentage of the market.
  • The United Kingdom is expected to grow at a CAGR of 12.9% over the period of forecasting.
  • In 2022, intestinal organoids held a market proportion of 37.42%.

“The National Institute of Allergy and Infectious Diseases, which conducts applied and basic research to assess and create therapeutics and examinations through a variety of contracts and research grants. Governments, commercial organizations, and private funding are all sources of R&D spending. This will almost certainly open up new opportunities for market development. “Says FMI analyst.

Competitive Landscape:

  • Next&Bio Inc. an enterprise that created an organoid-based accurate therapeutic search and discovery framework, inked a memorandum of understanding (MOU) with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) on the setting up of an alliance to realize the implementation of innovative precision medicine treatments employing cancer-organoids in May 2023.
  • In April 2023, scientists from the Princess Máxima Centre for Paediatric Oncology and the Hubrecht Institute in the Netherlands reported that organoids and CRISPR-Cas9 permitted them to acquire more knowledge into the tumors biology and biological ramifications of various changes to DNA in fibrolamellar carcinoma (FLC), a rare form of child’s liver cancer.
  • Cellesce Ltd
  • DefiniGEN
  • Qgel
  • Hubrecht Organoid Technology (HUB)
  • OcellO B.V.
  • STEMCELL Technologies Inc.
  • Thermo Fischer Scientific Inc.
  • Organovo Holdings Inc.
  • Takara Bio Inc.
  • Corning Incorporated
  • 3Dnamics Inc.

Key Segments Profiled in the Organoids Market Report:

By Product Type:

  • Intestinal Organoids
  • Hepatic Organoids
  • Pancreatic Organoids
  • Colorectal Organoids
  • Neural Organoids
  • Others

By Application:

  • Bio-banking
  • Biomedical Research and Drug Discovery
  • Regenerative Medicine
  • Cancer Research
  • Therapeutic Tools
  • Others

By End User:

  • Biopharmaceutical Companies
  • Contract Research Organizations
  • Academics and Research Institutes

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa